Project Grant R21CA317372
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $427K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90033, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute, under the Cancer Treatment Research program (CFDA 93.395), awarded the University of Southern California $560,863 on June 2, 2026, to support a five-year project (completion date May 31, 2031) investigating the role of P73-mediated Death Receptor 5 (DR5) induction in therapeutic response to Cyclin-Dependent Kinase (CDK) inhibition. The research focuses on understanding how selective CDK inhibitors, particularly CDK4/6 inhibitors approved...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $653,568 Project Grant to the University of California, Los Angeles, effective July 1, 2026, through June 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). The award supports research to enhance antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The project develops and evaluates drug candidates designed to improve the efficacy of existing cancer immunotherapies,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $648,626 to the University of California Irvine on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support a five-year project extending through March 31, 2031. This Project Grant funds fundamental research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically examining how PD-1 (Programmed Death-1) inhibition affects tumor...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Southern California a $3,036,844 Project Grant on August 11, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate a wireless thermos-activator device for controllable solid tumor immunotherapy. The project addresses critical limitations in Chimeric Antigen Receptor (CAR) T cell therapy by creating a portable, patient-friendly alternative to MRI-guided...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Southern California $479,234 under the Cancer Biology Research program (CFDA 93.396) on May 15, 2026, to conduct fundamental research on nonsense-mediated mRNA decay (NMD) mechanisms in cancer. The project, which extends through April 30, 2031, will deliver integrated computational and statistical analyses leveraging multi-omics data from the Cancer Genome Atlas (TCGA) and the Dependency Map (DepMap) to...
- Federal Grant Award Summary The University of Southern California received a $680,452 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on June 9, 2026, with completion targeted for May 31, 2029. This award supports the discovery and development of novel small-molecule compounds that selectively target the circadian regulatory complex composed of Brain and Muscle ARNT-Like Protein 1 (BMAL1) and Circadian Locomotor Output Cycles Kaput...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary New York University School of Medicine received a $695,852 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) awarded May 1, 2026, with completion targeted for April 30, 2031. This award funds fundamental research investigating T cell circuits within the lymphatic system during melanoma progression, with particular focus on tumor-draining lymph nodes (TDLNs) as immune surveillance hubs. The research aims to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded $660,808 to the Regents of the University of Michigan to investigate the durability and function of tissue-resident memory T cells (TRM) in melanoma immunotherapy response. The five-year project, awarded April 7, 2026, and concluding March 31, 2031, will deliver fundamental cancer immunology research examining how TRM cells established at primary melanoma...